1 The EIC Accelerator Project
EIC Accelerator Program Overview
The European Innovation Council (EIC) Accelerator program is designed to support the development and scaling of innovative startups and small to medium-sized enterprises (SMEs) in Europe, particularly those operating in the DeepTech sector. Launched under the Horizon Europe framework, the program aims to bridge the funding gap faced by ambitious companies seeking to bring groundbreaking technologies to market. The EIC Accelerator provides financial support in two main forms: grants and equity investments.
Financial Support Structure
Purpose of the EIC Accelerator
The primary objective of the EIC Accelerator is to foster innovation and support the European DeepTech ecosystem. By providing financial resources and mentoring, the program aims to help startups transform innovative ideas into viable products and services. The EIC Accelerator promotes collaboration between public and private sectors, enhancing access to additional funding sources and enabling companies to achieve substantial growth. This support is particularly crucial in highly competitive markets where innovative technologies require significant investment and development time.
Role in Scaling and Funding
The EIC Accelerator plays a pivotal role in helping companies scale their operations by providing not only financial support but also strategic guidance. Successful applicants benefit from access to a network of investors, business coaches, and industry experts, which enhances their visibility and credibility in the market. This ecosystem enables startups to secure additional private sector funding, thereby ensuring a robust financial foundation for their growth trajectory.
InBiome B.V. and the Molecular Culture Project
Company Overview: InBiome B.V., based in the Netherlands, has emerged as a pioneering force in the field of microbiome diagnostics. The company focuses on leveraging cutting-edge technology to develop solutions that address significant healthcare challenges.
Project Acronym: Molecular Culture
Project Description: The Molecular Culture project is a groundbreaking initiative that aims to create the world's first diagnostic test capable of detecting all bacterial species in a single assay. This innovative approach addresses a critical gap in current diagnostic methodologies, which often struggle to identify a comprehensive range of bacterial species due to limitations in conventional testing techniques.
Technology Basics and Background
The technology underpinning the Molecular Culture project hinges on advanced molecular biology techniques, particularly those that utilize next-generation sequencing (NGS) and bioinformatics. The test is designed to analyze complex microbiological samples, allowing for the identification and quantification of bacterial species present in a given sample. This capability is crucial for various applications, including clinical diagnostics, infectious disease management, and personalized medicine.
Traditional microbiological assays typically rely on culturing bacteria, which can be time-consuming and may miss non-culturable organisms. In contrast, Molecular Culture employs a culture-independent approach, enabling the detection of both culturable and non-culturable bacteria. This technology enhances the accuracy and speed of diagnostics, providing healthcare professionals with critical information for effective treatment decisions.
The implications of this technology are profound, particularly in the context of rising antibiotic resistance and the increasing prevalence of complex infections. By providing a comprehensive view of the bacterial landscape within a patient, Molecular Culture equips healthcare providers with the necessary data to tailor antibiotic therapies and improve patient outcomes.
Conclusion
In summary, the EIC Accelerator program serves as a vital catalyst for innovation within the European DeepTech sector, exemplified by the success of InBiome B.V. and its Molecular Culture project. The combination of grant funding and equity investment enables startups to advance their groundbreaking technologies, paving the way for transformative solutions in healthcare and beyond. Through initiatives like Molecular Culture, the EIC Accelerator contributes to the evolution of diagnostics, addressing critical needs in modern medicine and enhancing public health outcomes.
2 The Funding Rounds
inBiome B.V. (Netherlands): Funding and Financing Overview Since EIC Accelerator Award
Background:
inBiome B.V., based in the Netherlands, is a diagnostic technology innovator recognized for its Molecular Culture platform, which enables rapid detection of all bacterial species in clinical samples. The company received EIC Accelerator funding following the January 11, 2023 cut-off.
Financing Raised and Funding Rounds
- Up to €2.5 million as a grant component
- Potential equity investments up to €15 million via the EIC Fund
- Nature of Funding:
- Timing:
- Application submitted: January 11, 2023
- Results announced: Early March/April 2023
- Grant agreement preparation followed immediately after selection; actual disbursement timing is subject to final contract approval.
Investor Information
Amounts & Details Related to Funding Rounds
| Date | Type | Amount | Key Investor(s) |
|---|---|---|---|
| Q1/Q2 2023 | EIC Accelerator | Up to €17.5 million | European Innovation Council Fund |
</em>Blended finance cap: up to €2.5M grant + max €15M equity per project under standard terms; actual figures may differ pending contractual specifics but typically do not exceed these limits for any one beneficiary.
Company Valuations
There are no public records or formal disclosures from either private market intelligence platforms or official Dutch filings that report an updated post-money valuation for inBiome following its receipt of EIC funding through May 2025.
Valuation data would typically become available only if another VC round occurred or if required by regulatory filings tied to significant share issuances—neither event appears documented publicly at this time.
Exit Events (IPO/Buyouts/Acquisitions)
As of May 2, 2025:
- There have been no reported IPOs involving inBiome.
- No buyout offers or confirmed acquisitions have been disclosed via business registries, press releases from relevant stock exchanges/governing bodies, nor through major startup databases.
- The company remains independently operated with support from EU innovation initiatives focused on commercialization rather than near-term exit events.
Summary Table
| Category | Status / Details |
|---|---|
| Last major funding round | Q1/Q2 2023 — EIC Accelerator blended finance |
| Disclosed amount | Up to €17.5 million possible under program rules |
| Main investor | European Innovation Council Fund |
| Other recent investors | None publicly disclosed |
| Valuation post-funding | Not publicly available |
| Exit events | None reported as of May 02, 2025 |
Note: All figures reflect maximum amounts permitted under prevailing EU/EIC terms; individual company contracts may differ slightly depending on negotiation outcomes and milestone achievements set out by regulators/funders.
Sources
- EIC Accelerator-backed Molecular Culture receives FDA Breakthrough Device Designation
- EIC Work Programme – Official Document
- EIT Health – Conditional Equity Commitment List
- Strata.team – January 2023 Winners & Statistics
3 The Press Releases
inBiome B.V.: Advancements and Updates Since EIC Accelerator Funding
inBiome B.V., a leading innovator in diagnostic technologies, received the EIC Accelerator grant in January 2023 to support the go-to-market strategy of its first in vitro diagnostic (IVD) device. This Netherlands-based company is pioneering a revolutionary approach to bacterial diagnostics with its patented Molecular Culture technology.
Technology Advancements
- Molecular Culture ID: inBiome's technology is designed to detect over 200 bacterial species from various bodily samples, offering same-day diagnoses that are significantly more accurate and faster than traditional methods. This advancement represents a major breakthrough in the timely and effective treatment of bacterial infections.
- PCR Technology Integration: The company has further enhanced its capabilities by integrating cutting-edge PCR technology, enabling the simultaneous identification of hundreds of bacterial pathogens in a single test. This technology streamlines diagnostic workflows and replaces traditional bacterial culture methods, which often take days to provide results.
Recognition and Partnerships
- FDA Breakthrough Device Designation: inBiome's Molecular Culture ID technology received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in September 2024. This designation highlights the technology's potential to transform infectious disease diagnostics.
- U.S. Market Introduction: inBiome plans to introduce its technology to the U.S. market by early 2026. The company is collaborating with leading U.S. hospitals on implementation studies to ensure seamless integration into U.S. hospital workflows.
Press Releases and Updates
Recent press releases on inBiome's website highlight significant advancements and recognition. These include the FDA Breakthrough Device Designation and ongoing efforts to revolutionize bacterial diagnostics, particularly in addressing the global health threat of antimicrobial resistance.
Impact and Future Directions
inBiome's innovative solutions aim to enhance patient care by enabling quicker treatment decisions and reducing healthcare costs. With its technology optimized for joint aspirates and other critical infections, inBiome is poised to make a significant impact on the field of infectious disease diagnostics.
Sources
- EIC Accelerator winners and statistics January 2023 - Strata.team
- Press Release - Amsterdam, September 26 2024 - inbiome
- Press Release - Amsterdam, September 20 2024 - inbiome
- inbiome: Home
4 The Technology Advancements
Inbiome B.V. Advancements Post-EIC Accelerator Funding Since securing EIC Accelerator funding in 2023, Dutch molecular diagnostics firm Inbiome B.V. has achieved significant milestones in technology development, clinical validation, and commercialization. Below is a synthesis of their progress:Technology Improvements & New Features
- FDA Breakthrough Device Designation: Received in September 2024 for its Molecular Culture ID platform, recognizing its potential to provide faster and more accurate bacterial diagnostics compared to traditional methods.
- IVDR Certification: Obtained EU certification in April 2025, enabling immediate deployment of the platform across European hospitals for identifying bacteria in critical samples (e.g., cerebrospinal fluid, synovial fluid) within five hours.
- AI-Driven Detection: Enhanced untargeted PCR with AI to identify over 200 bacterial species—including uncultivable or antibiotic-treated pathogens—while detecting unknown pathogens at the phylum level.
Market Demonstrations & Clinical Validation
- Clinical Trials: Ongoing studies at Amsterdam UMC’s Emma Children’s Hospital demonstrated reduced antibiotic use in newborns with fever. An Austrian study reported a 30% higher detection rate for joint infections compared to traditional culture methods.
- Hospital Partnerships: Collaborated with Maastricht University Medical Center and over 15 EU/U.S. hospitals for real-world validation trials focused on workflow optimization and treatment delays.
- Commercial Deployment: Fully certified platform now operational across EU hospitals, with plans for U.S. market entry by early 2026 following FDA designation.
Scientific & Intellectual Property Developments
While no new patents or peer-reviewed studies are explicitly cited:- Clinical Data Highlights: Reported a 21% higher pathogen detection rate in joint infections compared to culture-based methods during collaborations with Amsterdam UMC.
- Microbiome Applications: Expanded services include quality control testing for probiotics/cosmetics and skin microbiota analysis using Molecular Culture® technology.
Vision & Funding Outlook
Inbiome aims to achieve same-day diagnostics for all infectious diseases by 2030 through continued R&D investments supported by an upcoming funding round targeting commercialization acceleration .Sources (All accessed via provided search results):
5 The Partnerships and Customers
Overview of inBiome B.V.
InBiome B.V., headquartered in Amsterdam, Netherlands, is a pioneering company in the field of diagnostic technologies. Since receiving the European Innovation Council (EIC) Accelerator funding in January 2023, inBiome has made significant strides in advancing its innovative molecular diagnostic platforms.
Partnerships and Customers
InBiome has established partnerships with several notable institutions and hospitals, including:
- Amsterdam University Medical Center (UMC): Collaborations focus on real-world validation trials and optimizing workflows to enhance diagnostic efficiency.
- Maastricht University Medical Center: Participates in clinical trials to validate inBiome's diagnostic technologies.
- Over 15 hospitals in the US and Europe: Engaged in real-world validation studies to support the commercial deployment of inBiome’s diagnostic systems.
These partnerships are crucial for validating the clinical impact of inBiome's technologies, such as the Molecular Culture ID platform, which has demonstrated a 21% higher pathogen detection rate in joint infections compared to traditional methods.
Nature of New Relationships
InBiome's new relationships are primarily focused on expanding its presence in the European and US markets. The recent IVDR certification and FDA Breakthrough Device Designation have positioned inBiome as a leader in rapid infection diagnostics, facilitating its entry into the US market by 2026.
Purpose and Impact
The purpose of these relationships is to accelerate the commercialization and research and development of inBiome's diagnostic technologies. By collaborating with major healthcare institutions, inBiome aims to reduce diagnostic delays, enhance patient outcomes, and combat antimicrobial resistance through precise and rapid pathogen detection.
Market Positioning and Technology Advancements
These partnerships and certifications position inBiome as a key player in the diagnostics market, offering solutions that significantly outperform traditional culture-based methods. The integration of AI and molecular technologies in its platforms enables faster and more accurate diagnostics, which will be pivotal in scaling the company's offerings globally.
The partnerships will also facilitate technology advancements by providing real-world validation and feedback, allowing inBiome to refine its platforms and meet the evolving needs of the healthcare sector. Furthermore, the forthcoming funding round will support these efforts by accelerating commercial and R&D activities.
Conclusion
InBiome B.V.'s strategic partnerships and regulatory achievements have poised the company for significant growth and technological advancements. Its focus on rapid diagnostic solutions is set to revolutionize the field of infectious disease diagnostics, aligning with its ambitious goal of achieving same-day diagnostics for all infectious diseases by 2030.
Sources: - inbiome: Home
- Press Release - Amsterdam, September 26 2024
- Inbiome Shatters Diagnostic Delays: IVDR-Certified Platform
- Inbiome's Bacterial Identification System Secures IVDR Certification
6 The Hiring and Company Growth
InBiome B.V.: EIC Accelerator Winner
InBiome B.V., a pioneering molecular diagnostics company based in the Netherlands, received EIC Accelerator funding on January 11, 2023. Since then, the company has continued to focus on its mission to redefine infection management through its innovative technologies.
Current Headcount and Team Size
InBiome has a team of approximately 24 employees, making it a relatively small but focused organization in the biotechnology sector.Hiring and Team Growth
While there is no specific information available on whether InBiome is currently hiring, the company's growth trajectory and technological advancements suggest a potential need for additional talent to support its rapid development and scaling efforts.Growth and Scaling
The funding from the EIC Accelerator is expected to significantly enhance InBiome's capabilities to grow and scale. This support will likely facilitate further innovation in their Molecular Culture technology, enabling the company to expand its reach and impact in the healthcare sector. The technology allows for faster and more accurate diagnostics, which could lead to better patient outcomes and reduced healthcare costs.Key Positions and Future Impact
While specific recent hires are not detailed, the addition of new team members would focus on enhancing InBiome's research, development, and commercialization efforts. These roles would be crucial for advancing the company's technological offerings and ensuring successful integration into clinical practices. By scaling its operations and talent pool, InBiome is positioned to make significant strides in microbiome analysis and bacterial diagnostics, contributing to more personalized and effective healthcare solutions.Management and Founding Team Changes
There is no publicly available information on major changes in InBiome's management or founding team since receiving the EIC Accelerator funding.Conclusion
InBiome's success in securing EIC Accelerator funding marks a significant milestone in its growth journey. As the company continues to innovate and expand its molecular diagnostics capabilities, it is poised to make a substantial impact on the future of healthcare, particularly in infection management and preventive care.Sources
7 The Media Features and Publications
inBiome B.V.: Innovations and Activities Since Receiving EIC Accelerator Funding
Overview of inBiome B.V.
inBiome B.V., a Netherlands-based company, specializes in molecular diagnostics, utilizing innovative technologies to accelerate bacterial diagnostics and microbiome analysis. The company's proprietary Molecular Culture technology enables rapid and accurate identification of bacteria, significantly improving healthcare outcomes by reducing diagnostic delays and enhancing treatment effectiveness.
Media Features and Publications
inBiome has been featured in several media outlets for its groundbreaking achievements in molecular diagnostics. A notable highlight is its recent IVDR certification, which allows the company to deploy its technology across EU hospitals, offering bacterial identification in under five hours—a significant improvement over traditional methods. This innovation has been recognized for its potential to combat antibiotic resistance and improve patient care.
Content from Publications
Publications have emphasized inBiome's role in revolutionizing healthcare through its advanced diagnostic platforms. The company's technology not only speeds up the diagnostic process but also enhances the accuracy of pathogen detection, which is crucial for targeted treatments and reducing unnecessary antibiotic use.
Podcasts or Interviews
There is currently no publicly available information on specific podcasts or interviews featuring the inBiome team. However, the company's leadership, including CEO Dries Budding and COO Jord Budding, have been involved in discussions about the company's vision and technological advancements.
Conference and Fair Visits
inBiome participates in various conferences and events focused on healthcare innovation and diagnostics. While specific details about recent conference visits are not available, the company's commitment to advancing healthcare through technology suggests active engagement in relevant industry forums.
Involvement in Events
inBiome's involvement in events is likely centered around showcasing its innovative diagnostic solutions and collaborating with healthcare providers and research institutions. The company's partnerships with Amsterdam UMC and other European hospitals highlight its engagement in real-world validation studies and optimizing workflows for faster diagnostics.
EIC Accelerator Funding
Receiving the EIC Accelerator funding in January 2023 marked a significant milestone for inBiome, supporting its mission to transform healthcare diagnostics. This funding has enabled the company to further develop its technology and expand its reach in the European market.
Sources: - About inbiome
- inBiome B.V.
- Inbiome B.V. full company profile on Creditsafe
- Microbiology services. - inbiome
- inbiome - Products, Competitors, Financials, Employees
- Inbiome Shatters Diagnostic Delays: IVDR-Certified Platform
- NUTRIM - Maastricht University
- inbiome: Home
Do you need EIC Accelerator support?
Here is a list of the key service options for the EIC Accelerator:
Full Writing Service
All proposal sections are written by Stephan Segler, PhD.
Advisory Service
You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.
AI Writer & Training
A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.